VIDEO: ASCO highlights in lung cancer outside of NSCLC
Click Here to Manage Email Alerts
Healio spoke with Karen L. Reckamp, MD, professor in medicine and director of the division of medical oncology at Cedars-Sinai Medical Center, about key studies in lung cancer from ASCO Annual Meeting.
She discussed research in lung cancer outside of non-small cell lung cancer presented at the meeting, including a trial evaluating the use of cisplatin pemetrexed and pembrolizumab (Keytruda, Merck) in patients with malignant pleural mesothelioma.
Reckamp also spoke about a study that investigated the use of maintenance talazoparib (Talzenna, Pfizer) in a subpopulations of patients with small cell lung cancer following standard therapy.
“This is one of the first studies to show that improvement in a selective subpopulation of small cell lung cancer, so [we’re] starting to understand that we can select for patients and potentially get better outcomes when we look at specific populations of small cell lung cancer, rather than lumping all those patients together.”
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts